Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

StockNews.com assumed coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a research report released on Thursday. The firm issued a hold rating on the biotechnology company’s ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Ionis Pharmaceuticals (IONS) announced that it has entered into a license agreement under which Sobi received exclusive rights in countries ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Shares of CASI stock opened at $2.21 on Tuesday. CASI Pharmaceuticals has a 12 month low of $2.04 and a 12 month high of $7.67. The stock has a market cap of $34.24 million, a P/E ratio of -0.99 ...

Endo agrees to divest its International Pharmaceuticals business, primarily operated by Paladin Pharma, to Knight Therapeutics for a total consideration of up to $99 million. Consideration consists of ...

March 11, 2025 /PRNewswire/ -- Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI) today announced it has entered into a definitive agreement to divest its International Pharmaceuticals business ...